This study was presented in phase 2, in a healthy population between 50 and 80 years of age, and it showed the use of Bentracimab reverts the antiplatelet effect of ticagrelor. The study included 205 adults mean age 61, 49% women, previously treated with aspirin and ticagrelor for 48 hrs. who were randomized 3:1 to…
ACC 2022 | APOLLO
Lipoprotein a (Lp a) is an important risk factor for atherothrombosis and atherosclerotic cardiovascular disease, but it has no approved treatments to this day. The aim of this randomized study in phase 1 was to assess adverse events and siRNA tolerance (small interfering RNA) to reduce liver production of Lp a and assess plasma concentration…